Literature DB >> 3496781

Collagen-binding of von Willebrand's factor antigen in the classification of von Willebrand's disease.

M J Duggan, D M DiMichele, M J Christian, L M Fink, W E Hathaway.   

Abstract

Analysis of the multimeric structure of von Willebrand's factor (vWf) was compared with vWf-binding to collagen in subjects' plasma. The percentage binding of vWf to collagen was determined by both an enzyme-linked immunosorbent assay (ELISA) method and quantitative immunoelectrophoresis. Normal subjects, type I von Willebrand's disease (vWd), and type II vWd were studied. The authors have found by correlating collagen-binding results with multimeric analysis that normal controls exhibit 85.4 +/- 5.1% collagen absorption of their vWf, patients with type I vWd 80.8 +/- 5.3%, whereas patients exhibiting a deficiency of high molecular weight vWf have 32.3 +/- 16.6% collagen absorption of vWf. The results suggest that this functional assay of vWf can be used in the classification of vWd and in the detection of new dysfunctional forms of vWf.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3496781     DOI: 10.1093/ajcp/88.1.97

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

1.  von Willebrand disease type 1 in Doberman Pinscher dogs: genotyping and prevalence of the mutation in the Buenos Aires region, Argentina.

Authors:  Julian A Crespi; Laura S Barrientos; Guillermo Giovambattista
Journal:  J Vet Diagn Invest       Date:  2017-12-22       Impact factor: 1.279

2.  Validation of a von Willebrand factor antigen enzyme-linked immunosorbent assay and newly developed collagen-binding assay.

Authors:  Hilary Burgess; Darren Wood
Journal:  Can J Vet Res       Date:  2008-10       Impact factor: 1.310

3.  Evaluation of laboratory methods to improve characterization of dogs with von Willebrand disease.

Authors:  Hilary J Burgess; J Paul Woods; Anthony C G Abrams-Ogg; R Darren Wood
Journal:  Can J Vet Res       Date:  2009-10       Impact factor: 1.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.